Nephros (NEPH) Cost of Revenue (2010 - 2026)

Nephros' Cost of Revenue history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 28.79% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 31.46% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, up 31.72% from the prior year.
• Cost of Revenue rose to $2.2 million in Q1 2026 per NEPH's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.2 million in Q1 2026 and bottomed at $1.0 million in Q4 2022.
• The 5-year median for Cost of Revenue is $1.5 million (2023), against an average of $1.5 million.
• Across the five-year window, Cost of Revenue soared 46.82% in 2022 and decreased 15.83% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $1.0 million in 2022, then climbed by 17.54% to $1.2 million in 2023, then grew by 13.14% to $1.4 million in 2024, then soared by 41.08% to $2.0 million in 2025, then grew by 12.75% to $2.2 million in 2026.
• Per Business Quant, the three latest NEPH Cost of Revenue figures stand at $2.2 million (Q1 2026), $2.0 million (Q4 2025), and $1.8 million (Q3 2025).